Moderna's $305 Bull Case Runs Through a Melanoma Filing Still Pending
Published on 11/10/2026 at 03:41 | Editorial boerse-global.de
Moderna enters the final stretch of 2026 with two stories pulling in opposite directions. One is a business that just turned a profit and raised its guidance. The other is a pipeline whose most valuable asset has yet to clear regulators. How investors weigh those two narratives will decide whether the stock's recent 5.3% advance marks the start of something or simply a pause.
A Quarter That Gave the Bulls Something Concrete
Third-quarter revenue came in at $1.3 billion, up 29% from a year earlier. Net income reached $162 million. Management credited stronger international sales of its COVID-19 vaccine and deliveries under government partnerships for the improved outlook, and lifted its 2026 revenue growth forecast to a range of 15% to 25%.
That combination — top-line expansion paired with a positive bottom line — is the strongest card Moderna holds right now. The question is whether the demand drivers behind it can be relied on beyond the reported period. Sales strength and earnings power are the yardsticks against which the next few quarters will be judged.
Two Banks, Two Very Different Price Tags
Wall Street's reaction split cleanly. Piper Sandler raised its target to $305 from $230 while keeping an Overweight rating, pointing to product sales in the third quarter and the upgraded growth guidance. The firm also expects a possible melanoma approval for Intismeran next year and believes Moderna's available funds will likely carry it back to profitability by 2028.
Goldman Sachs moved its target to $195 from $137 but stayed at Neutral. It too flagged growing confidence in Intismeran, with particular attention on upcoming kidney cancer data and near-term commercial opportunities in melanoma.
Should investors sell immediately? Or is it worth buying Moderna?
The gap between the two targets — more than $100 — captures the central investor dilemma: how much credit to extend to a company pivoting from a COVID vaccine franchise toward broader mRNA medicine. Both houses see progress; they disagree sharply on what it is worth.
Intismeran Carries the Weight of the Thesis
The individualized cancer therapy, developed with Merck and administered alongside Keytruda, sits at the heart of that pivot. In the Phase III melanoma trial, the combination cut the risk of recurrence or death by 42%. Moderna aims to file for approval in 2026, with a potential green light following in 2027.
Beyond melanoma, the company is testing similar approaches in lung, kidney and bladder cancers. Each additional indication opens fresh opportunity, provided the trials demonstrate durable benefit. That is why the market increasingly focuses on whether success in one program can be replicated across others.
A research and development day scheduled for November 12, 2026 — the same date as the analyst event — offers the next formal checkpoint. Priorities and development paths will matter most: which programs can broaden the business, and which still need further clinical evidence.
The Balance Sheet Buys Time, Not Certainty
Cash and investments stood at $8.0 billion at the end of September. A meaningful contribution came from convertible notes that generated roughly $2.6 billion in net proceeds. That cushion is a genuine asset, so long as it is directed toward programs with credible clinical and commercial prospects.
The Norovirus vaccine shows how selective that spending must remain. An interim analysis of its Phase III study missed the criteria for early success. No further cohort is planned for this season, and next steps will follow discussions with regulators. The setback raises the stakes on the more advanced programs.
What Has to Go Right
The bull case rests on a straightforward chain: regulatory filings succeed, new products launch, and revenue diversifies beyond seasonal respiratory demand. The cancer pipeline supports that vision. The development risk argues for caution in valuation while major programs still face clinical and regulatory hurdles.
Moderna has the revenue growth, the profit and the cash to fund the transition. What it does not yet have is a submitted melanoma application. Until that changes, the raised targets from Piper Sandler and Goldman Sachs are bets on execution — and the November events will be the first real test of whether the company can back them up.
Ad
Moderna Stock: New Analysis - 10 November
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
